title: A phase II trial with rosiglitazone in liposarcoma patients.
abstract: Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4 mg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor gamma (PPARgamma), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2 - 16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARgamma activity does not correlate with the clinical evolution.
authors.affiliation: Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Herestraat 49, Leuven 3000, Belgium. Guy.Debrock@zol.be
authors.forename: G
authors.initials: G
authors.lastname: Debrock
authors.forename: V
authors.initials: V
authors.lastname: Vanhentenrijk
authors.forename: R
authors.initials: R
authors.lastname: Sciot
authors.forename: M
authors.initials: M
authors.lastname: Debiec-Rychter
authors.forename: R
authors.initials: R
authors.lastname: Oyen
authors.forename: A
authors.initials: A
authors.lastname: Van Oosterom
mesh_terms: D000328:Adult; D004268:DNA-Binding Proteins; D018450:Disease Progression; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008080:Liposarcoma / Q000188:drug therapy*; D008297:Male; D008830:Microbodies; D008875:Middle Aged; D009687:Nuclear Proteins; D018160:Receptors, Cytoplasmic and Nuclear; D012097:Repressor Proteins; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D014157:Transcription Factors; D016896:Treatment Outcome; D016335:Zinc Fingers
chemical_list: D004268:DNA-Binding Proteins; D005343:Fibrinolytic Agents; D009687:Nuclear Proteins; D018160:Receptors, Cytoplasmic and Nuclear; D012097:Repressor Proteins; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077154:Rosiglitazone